Catalyst Funds Management Pty Ltd Acquires 22,100 Shares of Merck & Co., Inc. $MRK

Catalyst Funds Management Pty Ltd increased its holdings in Merck & Co., Inc. (NYSE:MRK) by 185.7% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 34,000 shares of the company’s stock after purchasing an additional 22,100 shares during the period. Merck & Co., Inc. comprises about 0.8% of Catalyst Funds Management Pty Ltd’s portfolio, making the stock its 19th largest holding. Catalyst Funds Management Pty Ltd’s holdings in Merck & Co., Inc. were worth $3,579,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of MRK. Kingdom Financial Group LLC. purchased a new position in Merck & Co., Inc. in the fourth quarter worth about $25,000. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $31,000. High Note Wealth LLC lifted its holdings in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after purchasing an additional 109 shares in the last quarter. Tucker Asset Management LLC purchased a new position in Merck & Co., Inc. in the 4th quarter worth approximately $34,000. Finally, Wealth Watch Advisors INC purchased a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $34,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Sichuan Kelun-Biotech reported encouraging late-stage lung cancer data for a Keytruda combination, with the treatment beating Keytruda alone and improving confidence in Merck’s cancer pipeline. Kelun, Merck’s lung cancer combo improves survival in late-stage China trial
• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion for Keytruda plus Padcev as a perioperative treatment for certain bladder cancer patients, which could expand the drug pair’s commercial reach if formally approved. Merck Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev
• Positive Sentiment: Additional coverage highlighted positive EU recommendations and trial momentum across Merck’s oncology portfolio, suggesting the company is building new growth drivers ahead of future Keytruda patent pressure. Merck stock jumps as Keytruda combo trials boost cancer pipeline
• Neutral Sentiment: Some commentary noted Gardasil sales remain weak due to soft demand in China and other markets, which is a reminder that Merck still has headwinds outside oncology. Will Weak Gardasil Sales Continue to Ail MRK’s Vaccines Sales in 2026?
• Neutral Sentiment: Merck’s recent run-up also reflects broader investor optimism after strong quarterly results and improving sentiment around its pipeline, rather than a single one-day event. Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Merck & Co., Inc. Trading Up 5.8%

Shares of NYSE:MRK opened at $122.55 on Friday. The business’s 50-day moving average is $115.92 and its 200 day moving average is $110.22. Merck & Co., Inc. has a 1 year low of $75.40 and a 1 year high of $125.14. The firm has a market capitalization of $302.67 billion, a P/E ratio of 34.52, a P/E/G ratio of 2.76 and a beta of 0.18. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the prior year, the company posted $2.22 EPS. The firm’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Cantor Fitzgerald lifted their price objective on Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Wells Fargo & Company lowered their target price on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. JPMorgan Chase & Co. upped their target price on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a report on Monday, April 6th. Finally, Barclays began coverage on Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.